Diffuse Large B Cell Lymphoma Refractory Clinical Trials

19 clinical trials for Diffuse Large B Cell Lymphoma Refractory across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — RECRUITING · PHASE3
• Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL — RECRUITING · PHASE2
• A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) — RECRUITING · PHASE1
• Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies — RECRUITING · PHASE1
• Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse — RECRUITING · PHASE2
• CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma — RECRUITING · PHASE1
• A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL — RECRUITING · PHASE2
• Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy — COMPLETED · PHASE2
• Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas — NOT_YET_RECRUITING · PHASE2
• A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma — TERMINATED · PHASE1
• R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma — WITHDRAWN · PHASE2
• Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL — OTHER · PHASE2
• Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE2
• Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. — COMPLETED · PHASE2
• Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL — OTHER · PHASE2
• Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL — OTHER · PHASE1
• Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma — COMPLETED · PHASE1
• Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma — TERMINATED · PHASE2

Refine this search